We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test for Symptomatic Patients Aims to Revolutionize Cancer Diagnosis

By LabMedica International staff writers
Posted on 05 Jun 2023

Cancer patients generally seek medical attention from a primary care physician only after they begin experiencing related symptoms, such as unexplained weight loss, anemia, or abdominal discomfort. More...

But these symptoms are complex as they can be attributed to various causes. Early detection and intervention of cancer can significantly enhance patient outcomes. Hence, there is a need for innovative tools to speed up cancer diagnosis and potentially eliminate the need for invasive and costly investigations, thus more effectively triaging patients with non-specific cancer symptoms. Now, a novel blood test, capable of detecting over 50 types of cancer, has shown promising results, accurately detecting cancer in two-thirds of more than 5,000 individuals who had consulted their physician due to suspected symptoms. Furthermore, in 85% of these cases, the test accurately identified the original location of the cancer.

The SYMPLIFY study, sponsored by The University of Oxford (Oxford, UK), is the first large-scale evaluation of a multi-cancer early detection (MCED) test from GRAIL, LLC (Menlo Park, CA, USA) among individuals who had consulted their GP due to suspected cancer symptoms. The study enrolled 6,238 participants, aged 18 and above, across England and Wales who were referred for urgent imaging, endoscopy, or other diagnostic methods due to symptoms suggestive of potential gynecological, lung, lower GI or upper GI cancer, or who had presented with non-specific symptoms. All participants provided a blood sample for DNA extraction and testing.

The MCED test from GRAIL detected a cancer signal in 323 individuals, with 244 of these receiving a cancer diagnosis, resulting in a positive predictive value (PPV) of 75.5%, negative predictive value (NPV) of 97.6%, and specificity of 98.4%. The overall sensitivity of the MCED test stood at 66.3%, ranging from 24.2% for stage I cancers to 95.3% for stage IV, and increasing with age and later cancer stage. The overall accuracy of the top CSO prediction following a positive MCED test was 85.2%. The study participants had a mean age of 62.1 years. Encouraged by the study outcomes, GRAIL now aims to broaden its market to include patients demonstrating symptoms linked to cancer, such as unexplained weight loss or abdominal pain.

GRAIL is planning to devise a new test specifically tailored for symptomatic patients, employing the same core technology used in its MCED test. The company hopes to have the new test available in months rather than years. Through a simple blood test, GRAIL aims to minimize reliance on costly scans or invasive biopsies as initial diagnostic procedures for cancer. Medical professionals have expressed enthusiasm about the potential impact of such blood tests in average-risk populations. These tests could serve as a crucial aid in making decisions concerning further diagnostic evaluation for patients. Nevertheless, the efficacy of such blood tests for early cancer detection and their influence on overall patient survival continues to be a topic of debate among clinicians.

“GRAIL’s earlier PATHFINDER study previously demonstrated that adding GRAIL’s MCED testing to standard of care screening more than doubled the number of cancers detected compared with standard screening alone in adults with no symptoms or suspicion of cancer. Now, the SYMPLIFY data confirm the potential benefit of methylation-based MCED blood tests as a diagnostic aid for use in the symptomatic patient population,” said Sir Harpal Kumar, President of GRAIL Europe. “These exciting results will inform our development of an optimized classifier for use in symptomatic patients with a suspicion of cancer.”

Related Links:
GRAIL, LLC


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.